Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Convertible Debt: 2016-2021

Historic Convertible Debt for Fortress Biotech (FBIO) over the last 3 years, with Sep 2021 value amounting to $18.1 million.

  • Fortress Biotech's Convertible Debt was N/A to $18.1 million in Q3 2021 from the same period last year, while for Sep 2021 it was $18.1 million, marking a year-over-year change of. This contributed to the annual value of $10.1 million for FY2017, which is 175.14% up from last year.
  • Fortress Biotech's Convertible Debt amounted to $18.1 million in Q3 2021, which was up 44.53% from $12.5 million recorded in Q2 2021.
  • Fortress Biotech's Convertible Debt's 5-year high stood at $18.1 million during Q3 2021, with a 5-year trough of $1.5 million in Q2 2017.
  • Over the past 1 years, Fortress Biotech's median Convertible Debt value was $12.5 million (recorded in 2021), while the average stood at $13.8 million.
  • Data for Fortress Biotech's Convertible Debt shows a peak YoY soared of 227.55% (in 2017) over the last 5 years.
  • Quarterly analysis of 2 years shows Fortress Biotech's Convertible Debt stood at $10.1 million in 2017, then followed by $18.1 million in 2021.
  • Its Convertible Debt was $18.1 million in Q3 2021, compared to $12.5 million in Q2 2021 and $10.7 million in Q1 2021.